Gemmer Asset Management buys $237,491 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Gemmer Asset Management scooped up 4 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 17, 2016. The investment management firm now holds a total of 3,947 shares of AbbVie Inc which is valued at $237,491.AbbVie Inc makes up approximately 0.12% of Gemmer Asset Management’s portfolio.

Other Hedge Funds, Including , Koshinski Asset Management reduced its stake in ABBV by selling 39 shares or 0.38% in the most recent quarter. The Hedge Fund company now holds 10,100 shares of ABBV which is valued at $607,717. AbbVie Inc makes up approx 0.30% of Koshinski Asset Management’s portfolio.Legacy Private Trust boosted its stake in ABBV in the latest quarter, The investment management firm added 1,570 additional shares and now holds a total of 36,329 shares of AbbVie Inc which is valued at $2,266,566. AbbVie Inc makes up approx 0.31% of Legacy Private Trust’s portfolio. First Financial Bank N.a. – Trust Division sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 6,658 shares of ABBV which is valued $421,518.Franklin Street Advisors Inc Nc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,666 additional shares and now holds a total of 164,178 shares of AbbVie Inc which is valued at $10,407,243. AbbVie Inc makes up approx 1.91% of Franklin Street Advisors Inc Nc’s portfolio.

AbbVie Inc closed down -0.98 points or -1.60% at $60.17 with 56,06,474 shares getting traded on Friday. Post opening the session at $61.45, the shares hit an intraday low of $60.15 and an intraday high of $61.515 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Leerink Partners Initiated AbbVie Inc on Oct 18, 2016 to “Mkt Perform”, Price Target of the shares are set at $70.AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.